TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript

TScan Therapeutics, Inc. ( TCRX ) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study

So this morning, I'll be providing a major strategic update to the company that we announced this morning. And just as a reminder, we are a publicly traded company, so I will make forward-looking statements during this presentation.

So as many of you recall, in the history of TScan, one of our core objectives has been to deliver TCR-engineered T cell therapies to patients with cancers. In fact, cancers with both heme and solid tumor malignancies. And last October, in October of 2025, we announced that we were pausing the solid tumor program in order to develop an in vivo engineering platform for solid tumors. So I'm excited today to announce that this program has actually made tremendous progress over the last year. And in fact, we have now, as of today, advanced two product candidates in this program into IND-enabling activities. So we've developed an in vivo lentiviral platform that efficiently delivers the genes for these TCRs into T cells in vivo. Those T cells get engineered and are able to clear target cancer